Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report)’s stock price gapped up before the market opened on Thursday. The stock had previously closed at $16.60, but opened at $17.30. Daiichi Sankyo shares last traded at $16.93, with a volume of 75,355 shares traded.
Analyst Upgrades and Downgrades
DSNKY has been the topic of several recent research reports. Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Monday, September 21st. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Check Out Our Latest Stock Report on DSNKY
Daiichi Sankyo Price Performance
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Sell-side analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current year.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Its business is centered on oncology, with additional operations in areas such as cardiovascular disease, immunology, and other serious medical conditions.
The company’s oncology portfolio includes antibody-drug conjugates, a technology designed to deliver potent cancer treatments more selectively to tumor cells. Daiichi Sankyo develops and commercializes medicines independently and through collaborations, including its partnership with AstraZeneca on trastuzumab deruxtecan, marketed as Enhertu, for certain cancer indications.
Daiichi Sankyo was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo.
Read More
- Five stocks we like better than Daiichi Sankyo
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
- Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
- Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?
- Failed Breakout in Tech? 3 Sectors Leading the Market Rotation
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
